After the intracavitary administration of 131l-labeled monoclonal antibody for treatment of primary brain tumors after surgical resection, a persistent rim of 18F-fluorodeoxyglucose (FDG) accumulation surrounding the cavity can be observed on PET. This rim, although it accumulates more FDG than adjacent normal brain tissue, is not necessarily associated with tumor. In our study, we examine the characteristics of the rim that indicate persistent tumor and tumor progression. Methods: Sequential PET studies obtained after treatment in 10 patients were reviewed and the results correlated with dosimetry and post-treatment histologie diagnoses. Results: The rim of FDG accumulation was seen on the first post-treatment scan obtained 1-3 mo after therapy and persisted unchanged over the 2-26 mo follow-up period. Pathologically, the nonmalignant rim was associated with marked increase of macrophage infiltrates. Modularity of the rim was associated with tumor. Conclusion: Our study demonstrates that a rim of FDG accumulation is seen after intracavitary administration of 131l-labeled monoclonal antibody therapy independent of the presence of malignant disease. Malignant recurrence is suggested by the development of new nodularity in the rim of FDG accumulation.
|Number of pages||5|
|Journal||Journal of Nuclear Medicine|
|Issue number||8 SUPPL.|
|State||Published - Dec 1 1998|
- Iodine-131-monoclonal antibody
- Primary brain tumors